PSA Screening in 2023

Posted by Gerald L. Andriole, Jr., MD | Jun 2023

Gerald L. Andriole, Jr., MD, presented “PSA Screening in 2023” during the 42nd Annual Ralph E. Hopkins Urology Seminar on February 1, 2023, in Jackson Hole, Wyoming.

How to cite: Andriole, Gerald L. “PSA Screening in 2023.” February 1, 2023. Accessed Apr 2024. https://grandroundsinurology.com/psa-screening-in-2023/

PSA Screening in 2023 – Summary

Gerald L. Andriole, Jr., MD, former Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University, reviews evidence supporting a more comprehensive family history and biomarkers in screening and treating prostate cancer. Dr. Andriole underscores the power of well-taken family histories, and suggests doctors counsel patients on their hereditary risk of prostate cancer, emphasizing the importance of one diagnosed high-risk family member, to reduce the rate of mortality.

Describing the Germline Mutations in Metastatic PCa, Dr. Andriole recommends all patients with prostate cancer who have certain characteristics be encouraged to speak to their physicians about whether they may need genetic testing for an inherited mutation. When looking in detail at polygenic risk scores (GRS,) knowledge of high GRS decreased the mortality rate.

Dr. Andriole highlights the Prompt Test, the direct-to-consumer, poly-genomic test in the US. In comparison, the UK Biobank data compares prevalence and hazard ratio to show the frequency is higher, some predict cancer aggressiveness. He expects to hear a lot about the prompt test in the future.

Dr. Andriole recommends identifying patients with clinically significant PCa earlier through a lower PSA cutpoint. He suggests using image-guided Micro US or MRI, or a transperineal biopsy to show potentially indicative biomarkers.

About The 42nd Annual Ralph E. Hopkins Urology Seminar:

The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 42nd iteration of the meeting took place from February 1st to 4th, 2023, in Jackson Hole, Wyoming.

For further educational activities from this conference, visit our collection page.

About The Author

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, is the global Chief Medical Officer at Prostatype Genomics. He previously was Professor and Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University. He also formerly served as the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 40 years of consistent contributions in the areas of prostate cancer screening and prevention research as well as BPH. He has contributed over 450 peer-reviewed publications. He chaired the Prostate Committee of NCI’s PLCO Cancer Screening Trial, the Steering Committee of the international REDUCE Chemoprevention Trial and the Prostate Committee of the SUO Clinical Trials Consortium. He is a member of the American Urological Association, the Academy of Master Surgical Educators of the American College of Surgeons, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies. He has received the Outstanding Achievement Award from the Urologic Oncology Branch of NCI, the Distinguished Clinician Award from Washington University, the Alumni Award from Jefferson Medical College and the Williams Award for Prostate Cancer Research Excellence from the AUA Urology Care Foundation, among others.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat